Board of Directors

Dr. Caforio, age 53, serves as Chairman of Bristol-Myers Squibb’s Board of Directors.

Dr. Caforio has been our Chief Executive Officer since May 2015. He was our Chief Executive Officer Designate from January to May 2015, our Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014.

From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010.

From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization.

Dr. Caforio is a member of the Board of Trustees of Hun School of Princeton and a member of the Business Roundtable, CEO Roundtable on Cancer and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Arduini, age 53, has been President and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since January 2012 and currently serves as a member of Integra’s Board of Directors.

He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, from 2005 to 2010.

Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business.

Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation.  Mr. Arduini also serves on the Board of Trustees of Susquehanna University.

Dr. Baselga, age 58, has been Physician-in-Chief of Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College since January 2013. From 2010 to 2012 Dr. Baselga served as Chief of the Hematology and Oncology Division and Associate Director of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. He also served as President of the American Association for Cancer Research from 2016 to 2017. He is a member of the National Academy of Medicine.

Dr. Baselga is an internationally recognized physician scientist who brings over 30 years of oncology experience to the Board.  

He is a Director of Varian Medical Systems, Foghorn Therapeutics and Breast International Group and is co-Founder of Tango Therapeutics.  Dr. Baselga also serves on the Advisory Boards of Aura Biosciences, Inc., Grail, Inc. Northern Biosciences, Inc., Robert H. Lurie Comprehensive Cancer Center at Northwestern University and Siteman Cancer Center, Washington University.

Robert Bertolini, age 56, brings to the Board significant experience in strategic and operational leadership both in and out of the finance function. Most recently, he was President and Chief Financial Officer of Bausch & Lomb where he played a key role in preparing the company for an initial public offering until its sale to Valeant Pharmaceuticals. Previously, Mr. Bertolini served as Executive Vice President and Chief Financial Officer at Schering-Plough Corporation, where he oversaw all key financial areas and played a key role in transforming operations and leading the acquisition of a significant business. Prior to joining Schering-Plough, Mr. Bertolini spent 20 years at PricewaterhouseCoopers LLP, leading its global pharmaceutical industry practice.

He is a Director of Charles River Laboratories International, Inc. and Idorsia Ltd.

Matthew Emmens, age 66, brings to the Board more than 40 years of experience in the biopharmaceutical industry, with significant management, business development and operations expertise. Mr. Emmens began his career in international pharmaceuticals with Merck & Co., Inc., where he helped to establish Astra Merck, the joint venture between Merck and Astra AB of Sweden, later becoming its President and CEO. A recognized biotech and pharma leader, Mr. Emmens served as President, Pharmaceuticals, for Merck KGaA; Chief Executive Officer and Chairman of Shire PLC; and President, Chief Executive Officer and Chairman of Vertex Pharmaceuticals. While at Shire, Mr. Emmens engineered an extraordinary revitalization, transforming Shire into one of the top specialty biopharma companies in the world. 

Mr. Grobstein, age 75, is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. Mr. Grobstein worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975.

He served as a Vice Chairman International Operations from 1993 to 1998, as Vice Chairman Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman Accounting and Auditing Services from 1984 to 1987.

He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy.

He also serves on the Board of Directors of the Peer Health Exchange, Inc.

Mr. Lacy, age 64, is a former Non-Executive Chairman of Dave & Buster’s Entertainment Inc. and previously served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporation, from 2000 to 2005.

Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014.

He is Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy.

Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University.

Mr. Paliwal, age 60, has served as President and Chief Executive Officer of Harman International, the connected technologies company for automotive, consumer and enterprise markets, since 2007. Mr. Paliwal served as Chairman of the Harman Board of Directors from July 2008 to March 2017 when Harman was acquired by Samsung Electronics Co., Ltd. Today it operates as a wholly-owned subsidiary of Samsung.

Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007.

Mr. Paliwal also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005.

Mr. Paliwal serves on the Board of Directors of the Business Advisory Council of Farmer School of Business, Miami University of Ohio and the U.S. India Business Council (USIBC). He also is a member of the CEO Business Roundtable in Washington, D.C.

With more than 35 years in the financial industry, Theodore (Ted) Samuels, age 63, brings to the Board extensive business and operational experience, particularly with respect to economics, capital markets and investment decision making. Mr. Samuels is the former President of Capital Guardian Trust Company and a former global equity portfolio manager at Capital Group, one of the most prominent investment management organizations in the world.

Mr. Samuels currently serves as a Director at Perrigo Company, PLC, and Stamps.com; and while at Capital Group served on numerous management and investment committees, with an eye towards long-term shareholder value creation. 

Dr. Sato, age 69, serves as Chairman of the Board of Denali Therapeutics, Inc. She previously served as a professor of management practice at the Harvard Business School from July 2005 to July 2017. From July 2005 to October 2014 she served as professor of the practice of molecular and cell biology at Harvard University.

In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal, and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chair of the Scientific Advisory Board at Vertex before being named President in 2000.

She serves as Chairman of VIR Biotechnology, Inc. and is on the Board of Directors of BorgWarner, Inc., Syros Pharmaceuticals and Peer Health Exchange, Inc.  She serves as Co-Chair on the Task Force on Science and Engineering at Harvard University and Co-Chair on the Advisory Council of LifeSci NYC.

Mr. Storch, age 62, has served as Chief Executive Officer of Storch Advisors, a global business and advisory firm, since November 2017.  From November 2013 to January 2014 he served as Chairman and Chief Executive Officer.  

He served as Chief Executive Officer of Hudson’s Bay Company from January 2015 to November 2017.  He also served as Chairman of Toys“R”Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys“R”Us from February 2006 to May 2013

Prior to joining Toys“R”Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company.

He is a Director of Fanatics, Inc.

Dr. Vousden, age 60, has been a Senior Group Leader at The Francis Crick Institute in London since February 2017 and Chief Scientist of Cancer Research UK (CRUK) since July 2016. From 2002 to 2016 she served as the Director of the CRUK Beatson Institute in Glasgow, prior to which she held leadership roles at the National Cancer Institute in Maryland from 1995 to 2002.

Dr. Vousden brings to the Board more than 30 years of experience leading ground breaking cancer research. She is a Fellow of the Royal Society and serves as a member of the Scientific Advisory Boards of Centro Nacional de Investigaciones Oncologicas, Grail, Inc., Ludwig Institute for Cancer Research, PMV Pharma, Raze Therapeutics and Swiss Institute of Experimental Cancer Research.  Dr. Vousden is also a Council member of the European Molecular Biology Organization.